Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joceline Fuchs

Urology Huntingdon Valley, PA Medical Doctor

NPI 1205122140 CMS profile 881196

1800 Byberry Rd Ste 1203, Huntingdon Valley, PA 19006

Open in the dashboard

General payments

$9,223

378 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joceline Fuchs of Huntingdon Valley, PA is reported in the CMS Open Payments database as having received $9,223 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,676 104
2024 General $1,818 81
2023 General $1,823 76
2022 General $787 39
2021 General $1,056 36
2020 General $373 13
2019 General $690 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joceline Fuchs
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Joceline Fuchs were reported at $2,676. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Joceline Fuchs Urology median Middle half National median
2019 $690 $480 $147–$1,201 $163
2020 $373 $246 $87–$645 $114
2021 $1,056 $358 $111–$1,000 $132
2022 $787 $476 $143–$1,263 $149
2023 $1,823 $560 $168–$1,461 $160
2024 $1,818 $563 $170–$1,464 $164
2025 $2,676 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $1,154 63 payments
  2. Dendreon Pharmaceuticals LLC $1,150 20 payments
  3. Janssen Biotech, Inc. $772 34 payments
  4. Astellas Pharma US Inc $708 37 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $694 28 payments
  6. Boston Scientific Corporation $560 14 payments
  7. AbbVie, Inc. $399 20 payments
  8. Medtronic, Inc. $346 5 payments
  9. Endo Pharmaceuticals Inc. $312 19 payments
  10. Pfizer Inc. $306 15 payments
  11. Other $2,822 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,218 377 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. PROVENGE $1,150 20 payments
  2. GEMTESA $1,025 65 payments
  3. Nubeqa $694 28 payments
  4. XTANDI $686 34 payments
  5. ERLEADA $578 31 payments
  6. Xofigo $552 22 payments
  7. XIAFLEX $524 30 payments
  8. ORGOVYX $359 13 payments
  9. BOTOX $348 17 payments
  10. INTERSTIM $346 5 payments
  11. Other $4,473 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

3,262

Median for Urology: 1,053

Drug cost

$1,778,048

Median for Urology: $101,464

Branded share of claims

40.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 34 $483,394
Erleada Apalutamide Brand 32 $457,398
Orgovyx Relugolix Brand 133 $393,960
Myrbetriq Mirabegron Brand 275 $202,721
Gemtesa Vibegron Brand 185 $158,342
Methenamine Hippurate Generic 265 $21,657
Tamsulosin Hcl Generic 611 $10,434
Solifenacin Succinate Generic 275 $8,607
Finasteride Generic 414 $7,084
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 29 $5,516

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$289,076

Of which drugs: $26,070

Medicare patients

1,294

Average age 76

Services billed

10,898

512 women, 782 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 31%
Ischemic heart disease 30%
Diabetes 29%
Cancer 26%
Depression 23%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 85 $11,976
Bcg live intravesical instillation, 1 mg J9030 Office 14 1,151 $2,622

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $313
$313 185 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $245
$245 — —
BOTOX
  • AbbVie, Inc. $148
$148 — —
XIAFLEX
  • Endo USA, Inc. $92
  • Endo Pharmaceuticals Inc. $35
$126 — —
ERLEADA
  • Janssen Biotech, Inc. $124
$124 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record